Search by Ticker
The following stock analysis is based on 8 years of data (i.e. since Aug 03, 2012). All the stock history has been downloaded.
Exelixis trades on the NasdaqGS exchange in USD dollars.
It is in the sector.
It is currently trading at $23.45 ($23.69 the previous day).
The next reporting date is in 2 days (2020 08 07).
CNN estimates profits for the upcoming quarter will be $0.12 per share ($226.2M). The current Canada / US exchange rate is 1.32937.
Over the past 12 months, $0 worth of shares have been purchased and $39294049 worth of shares have been sold by insiders.
The year over year average increase is 28.4% per year assuming steady exponential growth. The actual 5 year average is 70.8. Details on the individual increase in one year intervals is provided below.
|Past Performance||Average Price||Percent Change|
|1 year||20.020085227273||-0.4||- Below Average|
|2 year||20.108447488584||-18.9||- Below Average|
|3 year||24.796192468619||29.7||- Below Average|
|4 year||19.111457489879||223||+ Above Average|
|5 year||5.9164528301887||120.6||+ Above Average|
The worst drop it has had in recent years is -84.3%. It has a up and down shape to the stock curve, which means the stock can have significant gains followed by losses. Good for day trading, but needs to be watched if held for any significant amount of time.
Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out forThu, 30 Jul 2020 16:33:04 Exelixis (EXEL) doesnand't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.... Read Full Article
Exelixis to Release Second Quarter 2020 Financial Results on Thursday, August 6, 2020Wed, 29 Jul 2020 20:05:00 Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2020 financial results will be released on Thursday, August 6, 2020 after the markets close. At 5:30 p.m. EDT / 2:30 p.m. PDT, Exelixis management will host a conference call and webcast to discuss ...... Read Full Article
Will Exelixis (EXEL) Gain on Rising Earnings Estimates?Thu, 23 Jul 2020 16:20:04 Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.... Read Full Article
EXEL vs. RGEN: Which Stock Should Value Investors Buy Now?Wed, 22 Jul 2020 15:40:03 EXEL vs. RGEN: Which Stock Is the Better Value Option?... Read Full Article
Can Exelixis (EXEL) Keep the Earnings Surprise Streak Alive?Tue, 21 Jul 2020 16:10:04 Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.... Read Full Article
Exelixis Starts Study on Cabometyx Combo in Kidney CancerTue, 21 Jul 2020 14:00:02 Exelixis (EXEL) initiates CONTACT-03, a global phase III pivotal study of Cabometyx (cabozantinib) in combination with Rocheand's Tecentriq.... Read Full Article
Could The Exelixis, Inc. (NASDAQ:EXEL) Ownership Structure Tell Us Something Useful?Mon, 20 Jul 2020 16:43:21 If you want to know who really controls Exelixis, Inc. (NASDAQ:EXEL), then youand'll have to look at the makeup of its...... Read Full Article
Exelixis Announces Initiation of CONTACT-03 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Renal Cell CarcinomaMon, 20 Jul 2020 12:00:00 Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-03, a global phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with inoperable, locally advanced or metastatic renal cell carcinoma (RCC) who progressed during or following ...... Read Full Article
Did Hedge Funds Make The Right Call On Exelixis, Inc. (EXEL) ?Mon, 13 Jul 2020 14:45:29 We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, professional ...... Read Full Article
2 Stocks to Buy if Youand're Worried About Another Market CrashFri, 10 Jul 2020 11:16:00 Here are two stocks that might do just that: Exelixis (NASDAQ: EXEL) and Netflix (NASDAQ: NFLX). Its revenue largely depends on just one product: Cabometyx, a tyrosine kinase inhibitor (TKI) that specifically targets cancer cells. This cancer drug is approved ...... Read Full Article
Got $3,000? 3 Growth Stocks You Wonand't Regret BuyingFri, 10 Jul 2020 09:51:00 Although stock market corrections are part of the investing cycle, no investor, tenured or not, could have been prepared for what 2020 has offered. In about a four-month time span, the stock market has crammed in about a decade's worth of ...... Read Full Article
5 Booming Biotech Stocks to BuyFri, 03 Jul 2020 16:36:32 These five biotech stocks have already gone on heaters of 30% or more in 2020, and all of them still have plenty of upside to spare.... Read Full Article
Exelixis Announces Initiation of CONTACT-02 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Castration-Resistant Prostate CancerTue, 30 Jun 2020 12:00:00 Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-02, a global phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with metastatic castration-resistant prostate cancer (CRPC) who have been previously treated with one novel hormonal ...... Read Full Article
Exelixis (EXEL) in Focus: Stock Moves 7.6% HigherTue, 23 Jun 2020 03:02:03 Exelixis (EXEL) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.... Read Full Article
Exelixis to Webcast Virtual Fireside Chat as Part of the BofA Securities Napa Biopharma Conference on June 24, 2020Thu, 18 Jun 2020 20:05:00 Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will participate in a fireside chat as part of the virtual BofA Securities Napa Biopharma Conference on Wednesday, June 24, 2020 at 3:30 ...... Read Full Article
3 Stocks Growing Capex FastWed, 17 Jun 2020 17:42:02 Large spending to improve fixed assets may anticipate growth Continue reading...... Read Full Article
Hedge Funds Going Back and Forth About Exelixis, Inc. (EXEL)Fri, 12 Jun 2020 14:15:56 The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing 821 13F filings submitted by hedge funds and ...... Read Full Article
Exelixis Announces Initiation of CONTACT-01 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Non-small Cell Lung CancerThu, 11 Jun 2020 12:00:00 Exelixis, Inc. (NASDAQ: EXEL) today announced the initiation of CONTACT-01, a global phase 3 pivotal trial of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients with metastatic non-small cell lung cancer (NSCLC) who have been previously treated with an immune ...... Read Full Article
Exelixis (EXEL) Down 11.5% Since Last Earnings Report: Can It Rebound?Thu, 04 Jun 2020 15:31:03 Exelixis (EXEL) reported earnings 30 days ago. Whatand's next for the stock? We take a look at earnings estimates for some clues.... Read Full Article